NECTAR LIFESCIENCES LTD. Fair Value
NECLIFE · Healthcare · Current price ₹10.85
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹23 | -7% ROE fading to 12% over ~3 yrs, on ₹30 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is NECTAR LIFESCIENCES LTD. undervalued?
DocStoX estimates the fair value of NECTAR LIFESCIENCES LTD. at ₹23 per share, versus the current market price of ₹11. That puts the stock about +112.0% below our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹23). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹20 (bear) to ₹23 (base) to ₹26 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on NECTAR LIFESCIENCES LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.